SER News & Events

Serina Therapeutics announced that the first patient has been enrolled in the company's Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson's disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Serina Therapeutics files to sell 7.72M shares of common stock for holders

Serina Therapeutics announced that the FDA has cleared its investigational new drug application for SER-252, an investigational therapy for advanced Parkinson's disease. The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson's disease.

Serina Therapeutics received a deficiency notice from the NYSE American stating the company falls below continued listing criteria due to insufficient shareholders' equity and recent losses. The company reported shareholders' equity of $1.6M as of September 30, 2025, and recorded losses in three of its four most recent fiscal years. Serina must submit a compliance plan by February 8, detailing actions to regain compliance by July 9, 2027.